Pauric Bannigan
Overview
Explore the profile of Pauric Bannigan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bannigan P, Hickman R, Aspuru-Guzik A, Allen C
Adv Healthc Mater
. 2024 Aug;
13(29):e2401312.
PMID: 39155417
Over the last four decades, pharmaceutical companies' expenditures on research and development have increased 51-fold. During this same time, clinical success rates for new drugs have remained unchanged at about...
2.
Bao Z, Yung F, Hickman R, Aspuru-Guzik A, Bannigan P, Allen C
Drug Deliv Transl Res
. 2023 Dec;
14(7):1872-1887.
PMID: 38158474
Due to its cost-effectiveness, convenience, and high patient adherence, oral drug administration normally remains the preferred approach. Yet, the effective delivery of hydrophobic drugs via the oral route is often...
3.
Bao Z, Bufton J, Hickman R, Aspuru-Guzik A, Bannigan P, Allen C
Adv Drug Deliv Rev
. 2023 Sep;
202:115108.
PMID: 37774977
Over the past few years, the adoption of machine learning (ML) techniques has rapidly expanded across many fields of research including formulation science. At the same time, the use of...
4.
Wang X, Regenold M, Dunne M, Bannigan P, Allen C
Data Brief
. 2023 Sep;
50:109545.
PMID: 37767124
Thermosensitive liposomes in combination with localized mild hyperthermia can improve the delivery of drug to solid tumor sites. For this reason, thermosensitive liposome formulations of a range of chemotherapy drugs...
5.
Hickman R, Bannigan P, Bao Z, Aspuru-Guzik A, Allen C
Matter
. 2023 Apr;
6(4):1071-1081.
PMID: 37020832
Nanomedicines have transformed promising therapeutic agents into clinically approved medicines with optimal safety and efficacy profiles. This is exemplified by the mRNA vaccines against COVID-19, which were made possible by...
6.
Bao Z, Jung S, Bufton J, Bannigan P, Aguiar D, Allen C
Data Brief
. 2023 Mar;
48:109032.
PMID: 36950558
Advanced drug delivery strategies can be used to enhance the therapeutic effectiveness of locally delivered corticosteroids. Poly(δ-valerolactone--allyl-δ-valerolactone) microparticles (PVL--PAVL MPs) were evaluated for delivery of two corticosteroids, triamcinolone acetonide and...
7.
Zaslavsky J, Bannigan P, Allen C
Expert Opin Drug Deliv
. 2023 Jan;
20(2):241-257.
PMID: 36644850
Introduction: Interest in nanomedicines has surged in recent years due to the critical role they have played in the COVID-19 pandemic. Nanoformulations can turn promising therapeutic cargo into viable products...
8.
Bannigan P, Bao Z, Hickman R, Aldeghi M, Hase F, Aspuru-Guzik A, et al.
Nat Commun
. 2023 Jan;
14(1):35.
PMID: 36627280
Long-acting injectables are considered one of the most promising therapeutic strategies for the treatment of chronic diseases as they can afford improved therapeutic efficacy, safety, and patient compliance. The use...
9.
Regenold M, Wang X, Kaneko K, Bannigan P, Allen C
Drug Deliv Transl Res
. 2022 Dec;
13(4):1059-1073.
PMID: 36577832
Chemotherapy plays an important role in debulking tumors in advance of surgery and/or radiotherapy, tackling residual disease, and treating metastatic disease. In recent years many promising advanced drug delivery strategies...
10.
Regenold M, Kaneko K, Wang X, Peng H, Evans J, Bannigan P, et al.
J Control Release
. 2022 Dec;
354:19-33.
PMID: 36503069
Triggered drug delivery strategies have been shown to enhance drug accumulation at target diseased sites in comparison to administration of free drug. In particular, many studies have demonstrated improved targetability...